AKT1 and breast cancer: Everolimus, the inhibitor of the mammalian target of rapamycin (mTOR), has been shown to inhibit tumor cell growth through suppression of phosphoinositide 3-kinase (PI3K)/AKT pathway in breast cancer [27].